159 related articles for article (PubMed ID: 36577036)
21. The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation.
Zhang M; Wang B; Urabe G; Huang Y; Plutzky J; Kent KC; Guo LW
Cell Signal; 2019 Sep; 61():20-29. PubMed ID: 31075399
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
[TBL] [Abstract][Full Text] [Related]
23. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
Sartor GC; Powell SK; Brothers SP; Wahlestedt C
J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
[TBL] [Abstract][Full Text] [Related]
24. RVX-297- a novel BD2 selective inhibitor of BET bromodomains.
Kharenko OA; Gesner EM; Patel RG; Norek K; White A; Fontano E; Suto RK; Young PR; McLure KG; Hansen HC
Biochem Biophys Res Commun; 2016 Aug; 477(1):62-67. PubMed ID: 27282480
[TBL] [Abstract][Full Text] [Related]
25. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
26. Selective degradation of cellular BRD3 and BRD4-L promoted by PROTAC molecules in six cancer cell lines.
Yan Z; Lyu X; Lin D; Wu G; Gong Y; Ren X; Xiao J; Lou J; Huang H; Chen Y; Zhao Y
Eur J Med Chem; 2023 Jun; 254():115381. PubMed ID: 37084596
[TBL] [Abstract][Full Text] [Related]
27. CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation.
Carrasco K; Montersino C; Derviaux C; Saez-Ayala M; Hoffer L; Restouin A; Castellano R; Casassa J; Roche P; Pasquier E; Combes S; Morelli X; Collette Y; Betzi S
J Med Chem; 2022 Apr; 65(7):5660-5674. PubMed ID: 35348328
[TBL] [Abstract][Full Text] [Related]
28. Comparative structure-function analysis of bromodomain and extraterminal motif (BET) proteins in a gene-complementation system.
Werner MT; Wang H; Hamagami N; Hsu SC; Yano JA; Stonestrom AJ; Behera V; Zong Y; Mackay JP; Blobel GA
J Biol Chem; 2020 Feb; 295(7):1898-1914. PubMed ID: 31792058
[TBL] [Abstract][Full Text] [Related]
29. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
[No Abstract] [Full Text] [Related]
30. Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.
Ran X; Zhao Y; Liu L; Bai L; Yang CY; Zhou B; Meagher JL; Chinnaswamy K; Stuckey JA; Wang S
J Med Chem; 2015 Jun; 58(12):4927-39. PubMed ID: 26080064
[TBL] [Abstract][Full Text] [Related]
31. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.
Jiang W; Hou Q; Xu H; Yang K; Wang X; Zhang K; Zeng Y; Li W; Wang B; Luo G; Zhao X; Shen H; Xu Y; Wu X
J Med Chem; 2024 Jan; 67(2):1513-1532. PubMed ID: 38175809
[TBL] [Abstract][Full Text] [Related]
32. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses.
Liu CS; Rioja I; Bakr A; Veldwijk MR; Sperk E; Herskind C; Weichenhan D; Prinjha RK; Plass C; Schmezer P; Popanda O
Int J Cancer; 2022 Jul; 151(2):275-286. PubMed ID: 35239184
[TBL] [Abstract][Full Text] [Related]
33. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.
Chen X; Wu T; Du Z; Kang W; Xu R; Meng F; Liu C; Chen Y; Bao Q; Shen J; You Q; Cao D; Jiang Z; Guo X
Eur J Med Chem; 2024 Feb; 265():116080. PubMed ID: 38142510
[TBL] [Abstract][Full Text] [Related]
34. Dihydropyridine Lactam Analogs Targeting BET Bromodomains.
Jiang J; Sigua LH; Chan A; Kalra P; Pomerantz WCK; Schönbrunn E; Qi J; Georg GI
ChemMedChem; 2022 Jan; 17(1):e202100407. PubMed ID: 34932262
[TBL] [Abstract][Full Text] [Related]
35. Domain-Selective BET Ligands Yield Next-Generation Synthetic Genome Readers/Regulators with Nonidentical Cellular Functions.
Mohammed A; Waddell MB; Sutkeviciute I; Danda A; Philips SJ; Lang W; Slavish PJ; Kietlinska SJ; Kaulage M; Sourav D; Ansari AZ
J Am Chem Soc; 2023 Nov; ():. PubMed ID: 37923569
[TBL] [Abstract][Full Text] [Related]
36. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
[TBL] [Abstract][Full Text] [Related]
37. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
[TBL] [Abstract][Full Text] [Related]
38. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.
Roberts TC; Etxaniz U; Dall'Agnese A; Wu SY; Chiang CM; Brennan PE; Wood MJA; Puri PL
Sci Rep; 2017 Jul; 7(1):6153. PubMed ID: 28733670
[TBL] [Abstract][Full Text] [Related]
39. Bromodomain and extra-terminal domain bromodomain inhibition prevents synovial inflammation via blocking IκB kinase-dependent NF-κB activation in rheumatoid fibroblast-like synoviocytes.
Xiao Y; Liang L; Huang M; Qiu Q; Zeng S; Shi M; Zou Y; Ye Y; Yang X; Xu H
Rheumatology (Oxford); 2016 Jan; 55(1):173-84. PubMed ID: 26324948
[TBL] [Abstract][Full Text] [Related]
40. Precise Conformational Control Yielding Highly Potent and Exceptionally Selective BRD4 Degraders with Strong Antitumor Activity.
Hu J; Hu B; Xu F; Wang M; Qin C; McEachern D; Stuckey J; Wang S
J Med Chem; 2023 Jun; 66(12):8222-8237. PubMed ID: 37289649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
